Shopping Cart 0
Cart Subtotal
USD 0

Antibacterial Therapies Drug Development Pipeline Review, 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3995

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7990

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 11985
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023-Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65-a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.

Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the first- and second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita-EGFR inhibitors that targeted towards EGFR T790M-are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.

There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS-abemaciclib-is being developed in the pipeline.

Scope

The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.

How will immunotherapies such as atezolizumab contribute to growth?

What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

What are the common targets and mechanisms of action of pipeline therapies?

Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?

What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

How have the late-stage therapies performed in clinical trials?

How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

How do deal frequency and value compare between target families and molecule types?

What were the terms and conditions of key licensing deals?

Reasons to Buy

This report will allow you to

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.

Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

READ MORE

Table Of Content

Scope

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 16

Introduction 20

GBI Research Report Coverage 20

Tuberculosis Overview 20

Pneumonia 20

Methicillin-Resistant Staphylococcus aureus (MRSA) 21

Therapeutics Development 22

Tuberculosis 22

Pneumonia 24

Methicillin-Resistant Staphylococcus aureus (MRSA) 33

Therapeutics under Development by Companies 38

Tuberculosis 38

Pneumonia 41

Methicillin-Resistant Staphylococcus aureus (MRSA) 50

Therapeutics under Investigation by Universities/Institutes 55

Tuberculosis 55

Pneumonia 57

Methicillin-Resistant Staphylococcus aureus (MRSA) 60

Pipeline Products Glance 62

Tuberculosis 62

Pneumonia 65

Methicillin-Resistant Staphylococcus aureus (MRSA) 79

Products under Development by Companies 83

Tuberculosis 83

Pneumonia 86

Methicillin-Resistant Staphylococcus aureus (MRSA) 94

Products under Investigation by Universities/Institutes 101

Tuberculosis 101

Pneumonia 104

Methicillin-Resistant Staphylococcus aureus (MRSA) 106

Companies Involved in Therapeutics Development 109

Tuberculosis 109

Pneumonia 142

Methicillin-Resistant Staphylococcus aureus (MRSA) 203

Therapeutics Assessment 252

Tuberculosis 252

Pneumonia 263

Methicillin-Resistant Staphylococcus aureus (MRSA) 311

Dormant Projects 339

Tuberculosis 339

Pneumonia 343

Methicillin-Resistant Staphylococcus aureus (MRSA) 351

Discontinued Products 357

Tuberculosis 357

Pneumonia 357

Methicillin-Resistant Staphylococcus aureus (MRSA) 359

Product Development Milestones 360

Tuberculosis 360

Pneumonia 373

Methicillin-Resistant Staphylococcus aureus (MRSA) 405

Appendix 417

Methodology 417

Coverage 417

Secondary Research 417

Primary Research 417

Expert Panel Validation 417

Contact Us 417

Disclaimer 418


List Of Figure

List of Figures

Number of Products under Development for Tuberculosis 22

Number of Products under Development for Tuberculosis-Comparative Analysis 23

Number of Products under Development for Community Acquired Pneumonia 24

Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 26

Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27

Number of Products under Development for Ventilator Associated Pneumonia (VAP)-Comparative Analysis 28

Number of Products under Development for Pseudomonas aeruginosa Infections 29

Number of Products under Development for Pseudomonas aeruginosa Infections-Comparative Analysis 30

Number of Products under Development for Klebsiella pneumoniae Infections 31

Number of Products under Development for Klebsiella pneumoniae Infections-Comparative Analysis 32

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections-Comparative Analysis 34

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections-Comparative Analysis 37

Number of Products under Development by Companies, Tuberculosis 38

Number of Products under Development by Companies, Community Acquired Pneumonia 41

Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 42

Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 44

Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46

Number of Products under Development by Companies, Klebsiella pneumoniae Infections 48

Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50

Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53

Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54

Number of Products under Investigation by Universities/Institutes, Tuberculosis 55

Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 57

Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59

Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60

Comparative Analysis by Late Stage Development, Tuberculosis 62

Comparative Analysis by Clinical Stage Development, Tuberculosis 63

Comparative Analysis by Early Stage Products, Tuberculosis 64

Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65

Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66

Comparative Analysis by Early Stage Products, Community Acquired Pneumonia 67

Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68

Comparative Analysis by Early Stage Products, Hospital Acquired Pneumonia (HAP) 69

Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70

Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71

Comparative Analysis by Early Stage Products, Ventilator Associated Pneumonia (VAP) 72

Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73

Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74

Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75

Comparative Analysis by Early Stage Products, Pseudomonas aeruginosa Infections 76

Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77

Comparative Analysis by Early Stage Products, Klebsiella pneumoniae Infections 78

Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79

Comparative Analysis by Early Stage Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80

Comparative Analysis by Early Stage Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82

Assessment by Monotherapy Products, Tuberculosis 252

Assessment by Combination Products, Tuberculosis 253

Number of Products by Top 10 Targets, Tuberculosis 254

Number of Products by Stage and Top 10 Targets, Tuberculosis 254

Number of Products by Top 10 Mechanism of Actions, Tuberculosis 257

Number of Products by Stage and Top 10 Mechanism of Actions, Tuberculosis 257

Number of Products by Top 10 Routes of Administration, Tuberculosis 260

Number of Products by Stage and Top 10 Routes of Administration, Tuberculosis 260

Number of Products by Top 10 Molecule Types, Tuberculosis 262

Number of Products by Stage and Top 10 Molecule Types, Tuberculosis 262

Assessment by Monotherapy Products, Community Acquired Pneumonia 263

Number of Products by Targets, Community Acquired Pneumonia 264

Number of Products by Stage and Targets, Community Acquired Pneumonia 265

Number of Products by Mechanism of Actions, Community Acquired Pneumonia 266

Number of Products by Stage and Mechanism of Actions, Community Acquired Pneumonia 266

Number of Products by Routes of Administration, Community Acquired Pneumonia 267

Number of Products by Stage and Routes of Administration, Community Acquired Pneumonia 268

Number of Products by Molecule Types, Community Acquired Pneumonia 269

Number of Products by Stage and Top 10 Molecule Types, Community Acquired Pneumonia 269

Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP) 270

Assessment by Combination Products, Hospital Acquired Pneumonia (HAP) 271

Number of Products by Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272

Number of Products by Stage and Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272

Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274

Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274

Number of Products by Routes of Administration, Hospital Acquired Pneumonia (HAP) 276

Number of Products by Stage and Routes of Administration, Hospital Acquired Pneumonia (HAP) 276

Number of Products by Molecule Types, Hospital Acquired Pneumonia (HAP) 277

Number of Products by Stage and Molecule Types, Hospital Acquired Pneumonia (HAP) 278

Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP) 279

Assessment by Combination Products, Ventilator Associated Pneumonia (VAP) 280

Number of Products by Top 10 Targets, Ventilator Associated Pneumonia (VAP) 281

Number of Products by Stage and Top 10 Targets, Ventilator Associated Pneumonia (VAP) 282

Number of Products by Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 284

Number of Products by Stage and Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 285

Number of Products by Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 287

Number of Products by Stage and Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 288

Number of Products by Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 289

Number of Products by Stage and Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 290

Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections 291

Assessment by Combination Products, Pseudomonas aeruginosa Infections 292

Number of Products by Top 10 Targets, Pseudomonas aeruginosa Infections 293

Number of Products by Stage and Top 10 Targets, Pseudomonas aeruginosa Infections 293

Number of Products by Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 295

Number of Products by Stage and Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 296

Number of Products by Routes of Administration, Pseudomonas aeruginosa Infections 299

Number of Products by Stage and Routes of Administration, Pseudomonas aeruginosa Infections 299

Number of Products by Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301

Number of Products by Stage and Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301

Assessment by Monotherapy Products, Klebsiella pneumoniae Infections 303

Number of Products by Top 10 Targets, Klebsiella pneumoniae Infections 304

Number of Products by Stage and Top 10 Targets, Klebsiella pneumoniae Infections 304

Number of Products by Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306

Number of Products by Stage and Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306

Number of Products by Routes of Administration, Klebsiella pneumoniae Infections 308

Number of Products by Stage and Routes of Administration, Klebsiella pneumoniae Infections 308

Number of Products by Molecule Types, Klebsiella pneumoniae Infections 309

Number of Products by Stage and Molecule Types, Klebsiella pneumoniae Infections 310

Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 311

Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 312

Number of Products by Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313

Number of Products by Stage and Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313

Number of Products by Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316

Number of Products by Stage and Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316

Number of Products by Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319

Number of Products by Stage and Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319

Number of Products by Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321

Number of Products by Stage and Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321

Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 323

Number of Products by Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324

Number of Products by Stage and Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324

Number of Products by Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 325

Number of Products by Stage and Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 326

Number of Products by Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327

Number of Products by Stage and Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327

Number of Products by Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329

Number of Products by Stage and Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329

Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 330

Number of Products by Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331

Number of Products by Stage and Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331

Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333

Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333

Number of Products by Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335

Number of Products by Stage and Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335

Number of Products by Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 337

Number of Products by Stage and Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 33


List Of Table

List of Tables

Number of Products under Development for Tuberculosis 22

Number of Products under Development for Tuberculosis-Comparative Analysis 23

Number of Products under Development for Community Acquired Pneumonia 24

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 25

Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 26

Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27

Number of Products under Development for Ventilator Associated Pneumonia (VAP)-Comparative Analysis 28

Number of Products under Development for Pseudomonas aeruginosa Infections 29

Number of Products under Development for Pseudomonas aeruginosa Infections-Comparative Analysis 30

Number of Products under Development for Klebsiella pneumoniae Infections 31

Number of Products under Development for Klebsiella pneumoniae Infections-Comparative Analysis 32

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections-Comparative Analysis 34

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections-Comparative Analysis 37

Number of Products under Development by Companies, Tuberculosis 38

Number of Products under Development by Companies, Community Acquired Pneumonia 41

Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 43

Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 45

Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46

Number of Products under Development by Companies, Klebsiella pneumoniae Infections 49

Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50

Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53

Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54

Number of Products under Investigation by Universities/Institutes, Tuberculosis 55

Number of Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 57

Number of Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 57

Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 58

Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59

Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60

Number of Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 61

Comparative Analysis by Late Stage Development, Tuberculosis 62

Comparative Analysis by Clinical Stage Development, Tuberculosis 63

Comparative Analysis by Early Stage Development, Tuberculosis 64

Comparative Analysis by Unknown Stage Development, Tuberculosis 65

Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65

Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66

Comparative Analysis by Early Stage Development, Community Acquired Pneumonia 67

Comparative Analysis by Late Stage Development, Hospital Acquired Pneumonia (HAP) 67

Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68

Comparative Analysis by Early Stage Development, Hospital Acquired Pneumonia (HAP) 69

Comparative Analysis by Unknown Stage Development, Hospital Acquired Pneumonia (HAP) 69

Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70

Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71

Comparative Analysis by Early Stage Development, Ventilator Associated Pneumonia (VAP) 72

Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73

Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74

Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75

Comparative Analysis by Early Stage Development, Pseudomonas aeruginosa Infections 76

Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77

Comparative Analysis by Late Stage Development, Klebsiella pneumoniae Infections 77

Comparative Analysis by Clinical Stage Development, Klebsiella pneumoniae Infections 78

Comparative Analysis by Early Stage Development, Klebsiella pneumoniae Infections 78

Comparative Analysis by Late Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79

Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79

Comparative Analysis by Early Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80

Comparative Analysis by Unknown Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 81

Comparative Analysis by Clinical Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81

Comparative Analysis by Early Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81

Comparative Analysis by Clinical Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 81

Comparative Analysis by Early Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82

Products under Development by Companies, Tuberculosis 83

Products under Development by Companies, Community Acquired Pneumonia 86

Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 88

Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 89

Products under Development by Companies, Pseudomonas aeruginosa Infections 89

Products under Development by Companies, Klebsiella pneumoniae Infections 93

Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 94

Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 100

Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 100

Products under Investigation by Universities/Institutes, Tuberculosis 101

Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 104

Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 104

Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 104

Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 106

Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 106

Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 108

Tuberculosis-Pipeline by Abera Bioscience AB, 109

Tuberculosis-Pipeline by Akthelia Pharmaceuticals Limited, 109

Tuberculosis-Pipeline by Alvogen Korea Co., Ltd., 110

Tuberculosis-Pipeline by Anacor Pharmaceuticals, Inc., 111

Tuberculosis-Pipeline by Archivel Farma S.L., 111

Tuberculosis-Pipeline by AstraZeneca Plc, 112

Tuberculosis-Pipeline by Beech Tree Labs, Inc., 113

Tuberculosis-Pipeline by BioDiem Ltd, 113

Tuberculosis-Pipeline by BioLingus AG, 114

Tuberculosis-Pipeline by Biomar Microbial Technologies, 114

Tuberculosis-Pipeline by Bioversys AG, 115

Tuberculosis-Pipeline by Celgene Corporation, 115

Tuberculosis-Pipeline by Cellceutix Corporation, 116

Tuberculosis-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., 116

Tuberculosis-Pipeline by Crestone, Inc., 117

Tuberculosis-Pipeline by Dafra Pharma International Ltd., 117

Tuberculosis-Pipeline by Daiichi Sankyo Company, Limited, 118

Tuberculosis-Pipeline by Demuris Limited, 118

Tuberculosis-Pipeline by Eisai Co., Ltd., 119

Tuberculosis-Pipeline by Eli Lilly and Company, 120

Tuberculosis-Pipeline by Ensol Biosciences Inc., 120

Tuberculosis-Pipeline by EpiVax, Inc., 121

Tuberculosis-Pipeline by FIT Biotech Oy, 121

Tuberculosis-Pipeline by GangaGen Inc., 122

Tuberculosis-Pipeline by GlaxoSmithKline Plc, 122

Tuberculosis-Pipeline by Globeimmune, Inc., 123

Tuberculosis-Pipeline by Hager Biosciences, LLC, 123

Tuberculosis-Pipeline by Hsiri Therapeutics LLC, 124

Tuberculosis-Pipeline by Imaxio SA, 124

Tuberculosis-Pipeline by Immunitor, Inc., 125

Tuberculosis-Pipeline by ImmunoBiology Limited, 125

Tuberculosis-Pipeline by Inovio Pharmaceuticals, Inc., 126

Tuberculosis-Pipeline by Johnson & Johnson, 126

Tuberculosis-Pipeline by Lakewood-Amedex Inc, 127

Tuberculosis-Pipeline by Lipotek Pty Ltd., 127

Tuberculosis-Pipeline by Matinas BioPharma Holdings, Inc. , 128

Tuberculosis-Pipeline by Microbion Corporation, 128

Tuberculosis-Pipeline by Microbiotix, Inc., 129

Tuberculosis-Pipeline by NEARMEDIC PLUS, Ltd, 129

Tuberculosis-Pipeline by Novartis AG, 130

Tuberculosis-Pipeline by NovoBiotic Pharmaceuticals, LLC, 130

Tuberculosis-Pipeline by Otsuka Holdings Co., Ltd., 131

Tuberculosis-Pipeline by QureTech Bio AB, 131

Tuberculosis-Pipeline by Recce Pty Ltd, 132

Tuberculosis-Pipeline by Rodos BioTarget GmbH, 132

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023-Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

Summary

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising with increased smoking and the growing elderly population. Lung cancer is a leading cause of death worldwide, accounting for 1.69 million deaths in 2015. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65-a high-risk age range for lung cancer. As the aged population is projected to grow, the prevalence of lung cancer is anticipated to increase, acting as a driver for revenue growth.

The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is therefore shifting from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes, and the presence of various molecular aberrations.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta, while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Gilotrif, Conmana, Xalkori, Alecensa and Zykadia.

Opdivo and Keytruda are mAbs, immune checkpoint inhibitors targeted towards programmed cell death (PD) 1, and are recent market entrants. The former gained approval for treating advanced or metastatic squamous NSCLC in Japan in 2015 and in Australia and South Korea in 2016, and the latter gained approval in Japan in 2016 for the first- and second-line treatment of patients with PD-L1-positive unresectable advanced/recurrent NSCLC. Tagrisso and Olita-EGFR inhibitors that targeted towards EGFR T790M-are also recent market entrants, with the former gaining approval in Japan, Australia and South Korea, and the latter approved in South Korea in 2016 for advanced or metastatic patients with EGFR T790M mutation-positive metastatic NSCLC.

There are currently limited options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. A therapy that targets mutant KRAS-abemaciclib-is being developed in the pipeline.

Scope

The NSCLC Asia-Pacific market will be valued at $6.2 billion in 2023, growing from $3 billion in 2016 at a CAGR of 10.8%.

How will immunotherapies such as atezolizumab contribute to growth?

What effect will patent expirations of currently branded therapies have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.

What are the common targets and mechanisms of action of pipeline therapies?

Will the pipeline address unmet needs such as limited treatment options for squamous cell patients?

What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.

How have the late-stage therapies performed in clinical trials?

How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive landscape, with no targeted therapy currently available to address this patient subset?

The market forecasts indicate that Japan will contribute the most to the Asia-Pacific market value due to the emergence of novel therapies.

How will the annual cost of therapy and market size vary between the five Asia-Pacific markets?

How could changes in risk factors such as population age, smoking habits and pollution influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

How do deal frequency and value compare between target families and molecule types?

What were the terms and conditions of key licensing deals?

Reasons to Buy

This report will allow you to

Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.

Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.

Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.

Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.

Predict NSCLC market growth in the five Asia-Pacific markets, with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as the individual contributions of promising late-stage molecules to market growth.

Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

READ MORE

Scope

Table of Contents

GBI Research Report Guidance 2

Executive Summary 3

Table of Contents 4

List of Tables 6

List of Figures 16

Introduction 20

GBI Research Report Coverage 20

Tuberculosis Overview 20

Pneumonia 20

Methicillin-Resistant Staphylococcus aureus (MRSA) 21

Therapeutics Development 22

Tuberculosis 22

Pneumonia 24

Methicillin-Resistant Staphylococcus aureus (MRSA) 33

Therapeutics under Development by Companies 38

Tuberculosis 38

Pneumonia 41

Methicillin-Resistant Staphylococcus aureus (MRSA) 50

Therapeutics under Investigation by Universities/Institutes 55

Tuberculosis 55

Pneumonia 57

Methicillin-Resistant Staphylococcus aureus (MRSA) 60

Pipeline Products Glance 62

Tuberculosis 62

Pneumonia 65

Methicillin-Resistant Staphylococcus aureus (MRSA) 79

Products under Development by Companies 83

Tuberculosis 83

Pneumonia 86

Methicillin-Resistant Staphylococcus aureus (MRSA) 94

Products under Investigation by Universities/Institutes 101

Tuberculosis 101

Pneumonia 104

Methicillin-Resistant Staphylococcus aureus (MRSA) 106

Companies Involved in Therapeutics Development 109

Tuberculosis 109

Pneumonia 142

Methicillin-Resistant Staphylococcus aureus (MRSA) 203

Therapeutics Assessment 252

Tuberculosis 252

Pneumonia 263

Methicillin-Resistant Staphylococcus aureus (MRSA) 311

Dormant Projects 339

Tuberculosis 339

Pneumonia 343

Methicillin-Resistant Staphylococcus aureus (MRSA) 351

Discontinued Products 357

Tuberculosis 357

Pneumonia 357

Methicillin-Resistant Staphylococcus aureus (MRSA) 359

Product Development Milestones 360

Tuberculosis 360

Pneumonia 373

Methicillin-Resistant Staphylococcus aureus (MRSA) 405

Appendix 417

Methodology 417

Coverage 417

Secondary Research 417

Primary Research 417

Expert Panel Validation 417

Contact Us 417

Disclaimer 418


List Of Figure

List of Figures

Number of Products under Development for Tuberculosis 22

Number of Products under Development for Tuberculosis-Comparative Analysis 23

Number of Products under Development for Community Acquired Pneumonia 24

Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 26

Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27

Number of Products under Development for Ventilator Associated Pneumonia (VAP)-Comparative Analysis 28

Number of Products under Development for Pseudomonas aeruginosa Infections 29

Number of Products under Development for Pseudomonas aeruginosa Infections-Comparative Analysis 30

Number of Products under Development for Klebsiella pneumoniae Infections 31

Number of Products under Development for Klebsiella pneumoniae Infections-Comparative Analysis 32

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections-Comparative Analysis 34

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections-Comparative Analysis 37

Number of Products under Development by Companies, Tuberculosis 38

Number of Products under Development by Companies, Community Acquired Pneumonia 41

Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 42

Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 44

Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46

Number of Products under Development by Companies, Klebsiella pneumoniae Infections 48

Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50

Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53

Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54

Number of Products under Investigation by Universities/Institutes, Tuberculosis 55

Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 57

Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59

Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60

Comparative Analysis by Late Stage Development, Tuberculosis 62

Comparative Analysis by Clinical Stage Development, Tuberculosis 63

Comparative Analysis by Early Stage Products, Tuberculosis 64

Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65

Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66

Comparative Analysis by Early Stage Products, Community Acquired Pneumonia 67

Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68

Comparative Analysis by Early Stage Products, Hospital Acquired Pneumonia (HAP) 69

Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70

Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71

Comparative Analysis by Early Stage Products, Ventilator Associated Pneumonia (VAP) 72

Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73

Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74

Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75

Comparative Analysis by Early Stage Products, Pseudomonas aeruginosa Infections 76

Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77

Comparative Analysis by Early Stage Products, Klebsiella pneumoniae Infections 78

Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79

Comparative Analysis by Early Stage Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80

Comparative Analysis by Early Stage Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82

Assessment by Monotherapy Products, Tuberculosis 252

Assessment by Combination Products, Tuberculosis 253

Number of Products by Top 10 Targets, Tuberculosis 254

Number of Products by Stage and Top 10 Targets, Tuberculosis 254

Number of Products by Top 10 Mechanism of Actions, Tuberculosis 257

Number of Products by Stage and Top 10 Mechanism of Actions, Tuberculosis 257

Number of Products by Top 10 Routes of Administration, Tuberculosis 260

Number of Products by Stage and Top 10 Routes of Administration, Tuberculosis 260

Number of Products by Top 10 Molecule Types, Tuberculosis 262

Number of Products by Stage and Top 10 Molecule Types, Tuberculosis 262

Assessment by Monotherapy Products, Community Acquired Pneumonia 263

Number of Products by Targets, Community Acquired Pneumonia 264

Number of Products by Stage and Targets, Community Acquired Pneumonia 265

Number of Products by Mechanism of Actions, Community Acquired Pneumonia 266

Number of Products by Stage and Mechanism of Actions, Community Acquired Pneumonia 266

Number of Products by Routes of Administration, Community Acquired Pneumonia 267

Number of Products by Stage and Routes of Administration, Community Acquired Pneumonia 268

Number of Products by Molecule Types, Community Acquired Pneumonia 269

Number of Products by Stage and Top 10 Molecule Types, Community Acquired Pneumonia 269

Assessment by Monotherapy Products, Hospital Acquired Pneumonia (HAP) 270

Assessment by Combination Products, Hospital Acquired Pneumonia (HAP) 271

Number of Products by Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272

Number of Products by Stage and Top 10 Targets, Hospital Acquired Pneumonia (HAP) 272

Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274

Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Pneumonia (HAP) 274

Number of Products by Routes of Administration, Hospital Acquired Pneumonia (HAP) 276

Number of Products by Stage and Routes of Administration, Hospital Acquired Pneumonia (HAP) 276

Number of Products by Molecule Types, Hospital Acquired Pneumonia (HAP) 277

Number of Products by Stage and Molecule Types, Hospital Acquired Pneumonia (HAP) 278

Assessment by Monotherapy Products, Ventilator Associated Pneumonia (VAP) 279

Assessment by Combination Products, Ventilator Associated Pneumonia (VAP) 280

Number of Products by Top 10 Targets, Ventilator Associated Pneumonia (VAP) 281

Number of Products by Stage and Top 10 Targets, Ventilator Associated Pneumonia (VAP) 282

Number of Products by Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 284

Number of Products by Stage and Top 10 Mechanism of Actions, Ventilator Associated Pneumonia (VAP) 285

Number of Products by Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 287

Number of Products by Stage and Top 10 Routes of Administration, Ventilator Associated Pneumonia (VAP) 288

Number of Products by Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 289

Number of Products by Stage and Top 10 Molecule Types, Ventilator Associated Pneumonia (VAP) 290

Assessment by Monotherapy Products, Pseudomonas aeruginosa Infections 291

Assessment by Combination Products, Pseudomonas aeruginosa Infections 292

Number of Products by Top 10 Targets, Pseudomonas aeruginosa Infections 293

Number of Products by Stage and Top 10 Targets, Pseudomonas aeruginosa Infections 293

Number of Products by Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 295

Number of Products by Stage and Top 10 Mechanism of Actions, Pseudomonas aeruginosa Infections 296

Number of Products by Routes of Administration, Pseudomonas aeruginosa Infections 299

Number of Products by Stage and Routes of Administration, Pseudomonas aeruginosa Infections 299

Number of Products by Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301

Number of Products by Stage and Top 10 Molecule Types, Pseudomonas aeruginosa Infections 301

Assessment by Monotherapy Products, Klebsiella pneumoniae Infections 303

Number of Products by Top 10 Targets, Klebsiella pneumoniae Infections 304

Number of Products by Stage and Top 10 Targets, Klebsiella pneumoniae Infections 304

Number of Products by Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306

Number of Products by Stage and Top 10 Mechanism of Actions, Klebsiella pneumoniae Infections 306

Number of Products by Routes of Administration, Klebsiella pneumoniae Infections 308

Number of Products by Stage and Routes of Administration, Klebsiella pneumoniae Infections 308

Number of Products by Molecule Types, Klebsiella pneumoniae Infections 309

Number of Products by Stage and Molecule Types, Klebsiella pneumoniae Infections 310

Assessment by Monotherapy Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 311

Assessment by Combination Products, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 312

Number of Products by Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313

Number of Products by Stage and Top 10 Targets, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 313

Number of Products by Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316

Number of Products by Stage and Top 10 Mechanism of Actions, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 316

Number of Products by Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319

Number of Products by Stage and Top 10 Routes of Administration, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 319

Number of Products by Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321

Number of Products by Stage and Top 10 Molecule Types, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 321

Assessment by Monotherapy Products, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 323

Number of Products by Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324

Number of Products by Stage and Targets, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 324

Number of Products by Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 325

Number of Products by Stage and Mechanism of Actions, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 326

Number of Products by Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327

Number of Products by Stage and Routes of Administration, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 327

Number of Products by Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329

Number of Products by Stage and Molecule Types, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 329

Assessment by Monotherapy Products, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 330

Number of Products by Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331

Number of Products by Stage and Targets, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 331

Number of Products by Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333

Number of Products by Stage and Top 10 Mechanism of Actions, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 333

Number of Products by Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335

Number of Products by Stage and Routes of Administration, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 335

Number of Products by Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 337

Number of Products by Stage and Molecule Types, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 33


List Of Table

List of Tables

Number of Products under Development for Tuberculosis 22

Number of Products under Development for Tuberculosis-Comparative Analysis 23

Number of Products under Development for Community Acquired Pneumonia 24

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 25

Number of Products under Development for Hospital Acquired Pneumonia (HAP) 25

Number of Products under Development for Hospital Acquired Pneumonia (HAP)-Comparative Analysis 26

Number of Products under Development for Ventilator Associated Pneumonia (VAP) 27

Number of Products under Development for Ventilator Associated Pneumonia (VAP)-Comparative Analysis 28

Number of Products under Development for Pseudomonas aeruginosa Infections 29

Number of Products under Development for Pseudomonas aeruginosa Infections-Comparative Analysis 30

Number of Products under Development for Klebsiella pneumoniae Infections 31

Number of Products under Development for Klebsiella pneumoniae Infections-Comparative Analysis 32

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 33

Number of Products under Development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections-Comparative Analysis 34

Number of Products under Development for Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 35

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 36

Number of Products under Development for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections-Comparative Analysis 37

Number of Products under Development by Companies, Tuberculosis 38

Number of Products under Development by Companies, Community Acquired Pneumonia 41

Number of Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 43

Number of Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 45

Number of Products under Development by Companies, Pseudomonas aeruginosa Infections 46

Number of Products under Development by Companies, Klebsiella pneumoniae Infections 49

Number of Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 50

Number of Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 53

Number of Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 54

Number of Products under Investigation by Universities/Institutes, Tuberculosis 55

Number of Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 57

Number of Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 57

Number of Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 58

Number of Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 59

Number of Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 60

Number of Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 61

Comparative Analysis by Late Stage Development, Tuberculosis 62

Comparative Analysis by Clinical Stage Development, Tuberculosis 63

Comparative Analysis by Early Stage Development, Tuberculosis 64

Comparative Analysis by Unknown Stage Development, Tuberculosis 65

Comparative Analysis by Late Stage Development, Community Acquired Pneumonia 65

Comparative Analysis by Clinical Stage Development, Community Acquired Pneumonia 66

Comparative Analysis by Early Stage Development, Community Acquired Pneumonia 67

Comparative Analysis by Late Stage Development, Hospital Acquired Pneumonia (HAP) 67

Comparative Analysis by Clinical Stage Development, Hospital Acquired Pneumonia (HAP) 68

Comparative Analysis by Early Stage Development, Hospital Acquired Pneumonia (HAP) 69

Comparative Analysis by Unknown Stage Development, Hospital Acquired Pneumonia (HAP) 69

Comparative Analysis by Late Stage Development, Ventilator Associated Pneumonia (VAP) 70

Comparative Analysis by Clinical Stage Development, Ventilator Associated Pneumonia (VAP) 71

Comparative Analysis by Early Stage Development, Ventilator Associated Pneumonia (VAP) 72

Comparative Analysis by Unknown Stage Development, Ventilator Associated Pneumonia (VAP) 73

Comparative Analysis by Late Stage Development, Pseudomonas aeruginosa Infections 74

Comparative Analysis by Clinical Stage Development, Pseudomonas aeruginosa Infections 75

Comparative Analysis by Early Stage Development, Pseudomonas aeruginosa Infections 76

Comparative Analysis by Unknown Stage Development, Pseudomonas aeruginosa Infections 77

Comparative Analysis by Late Stage Development, Klebsiella pneumoniae Infections 77

Comparative Analysis by Clinical Stage Development, Klebsiella pneumoniae Infections 78

Comparative Analysis by Early Stage Development, Klebsiella pneumoniae Infections 78

Comparative Analysis by Late Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79

Comparative Analysis by Clinical Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 79

Comparative Analysis by Early Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 80

Comparative Analysis by Unknown Stage Development, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 81

Comparative Analysis by Clinical Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81

Comparative Analysis by Early Stage Development, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 81

Comparative Analysis by Clinical Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 81

Comparative Analysis by Early Stage Development, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 82

Products under Development by Companies, Tuberculosis 83

Products under Development by Companies, Community Acquired Pneumonia 86

Products under Development by Companies, Hospital Acquired Pneumonia (HAP) 88

Products under Development by Companies, Ventilator Associated Pneumonia (VAP) 89

Products under Development by Companies, Pseudomonas aeruginosa Infections 89

Products under Development by Companies, Klebsiella pneumoniae Infections 93

Products under Development by Companies, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 94

Products under Development by Companies, Community Acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) Infections 100

Products under Development by Companies, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 100

Products under Investigation by Universities/Institutes, Tuberculosis 101

Products under Investigation by Universities/Institutes, Hospital Acquired Pneumonia (HAP) 104

Products under Investigation by Universities/Institutes, Ventilator Associated Pneumonia (VAP) 104

Products under Investigation by Universities/Institutes, Pseudomonas aeruginosa Infections 104

Products under Investigation by Universities/Institutes, Klebsiella pneumoniae Infections 106

Products under Investigation by Universities/Institutes, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections 106

Products under Investigation by Universities/Institutes, Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections 108

Tuberculosis-Pipeline by Abera Bioscience AB, 109

Tuberculosis-Pipeline by Akthelia Pharmaceuticals Limited, 109

Tuberculosis-Pipeline by Alvogen Korea Co., Ltd., 110

Tuberculosis-Pipeline by Anacor Pharmaceuticals, Inc., 111

Tuberculosis-Pipeline by Archivel Farma S.L., 111

Tuberculosis-Pipeline by AstraZeneca Plc, 112

Tuberculosis-Pipeline by Beech Tree Labs, Inc., 113

Tuberculosis-Pipeline by BioDiem Ltd, 113

Tuberculosis-Pipeline by BioLingus AG, 114

Tuberculosis-Pipeline by Biomar Microbial Technologies, 114

Tuberculosis-Pipeline by Bioversys AG, 115

Tuberculosis-Pipeline by Celgene Corporation, 115

Tuberculosis-Pipeline by Cellceutix Corporation, 116

Tuberculosis-Pipeline by Chongqing Zhifei Biological Products Co., Ltd., 116

Tuberculosis-Pipeline by Crestone, Inc., 117

Tuberculosis-Pipeline by Dafra Pharma International Ltd., 117

Tuberculosis-Pipeline by Daiichi Sankyo Company, Limited, 118

Tuberculosis-Pipeline by Demuris Limited, 118

Tuberculosis-Pipeline by Eisai Co., Ltd., 119

Tuberculosis-Pipeline by Eli Lilly and Company, 120

Tuberculosis-Pipeline by Ensol Biosciences Inc., 120

Tuberculosis-Pipeline by EpiVax, Inc., 121

Tuberculosis-Pipeline by FIT Biotech Oy, 121

Tuberculosis-Pipeline by GangaGen Inc., 122

Tuberculosis-Pipeline by GlaxoSmithKline Plc, 122

Tuberculosis-Pipeline by Globeimmune, Inc., 123

Tuberculosis-Pipeline by Hager Biosciences, LLC, 123

Tuberculosis-Pipeline by Hsiri Therapeutics LLC, 124

Tuberculosis-Pipeline by Imaxio SA, 124

Tuberculosis-Pipeline by Immunitor, Inc., 125

Tuberculosis-Pipeline by ImmunoBiology Limited, 125

Tuberculosis-Pipeline by Inovio Pharmaceuticals, Inc., 126

Tuberculosis-Pipeline by Johnson & Johnson, 126

Tuberculosis-Pipeline by Lakewood-Amedex Inc, 127

Tuberculosis-Pipeline by Lipotek Pty Ltd., 127

Tuberculosis-Pipeline by Matinas BioPharma Holdings, Inc. , 128

Tuberculosis-Pipeline by Microbion Corporation, 128

Tuberculosis-Pipeline by Microbiotix, Inc., 129

Tuberculosis-Pipeline by NEARMEDIC PLUS, Ltd, 129

Tuberculosis-Pipeline by Novartis AG, 130

Tuberculosis-Pipeline by NovoBiotic Pharmaceuticals, LLC, 130

Tuberculosis-Pipeline by Otsuka Holdings Co., Ltd., 131

Tuberculosis-Pipeline by QureTech Bio AB, 131

Tuberculosis-Pipeline by Recce Pty Ltd, 132

Tuberculosis-Pipeline by Rodos BioTarget GmbH, 132

To know more information on Purchase by Section, please send a mail to support@kenresearch.com
chat_bubbleLet's Chat